In this study, we aimed to improve the efficacy of MD and AA+MD against GBM cells via pharmacological modulation using small molecule inhibitors of two commonly deregulated signaling pathways in GBM—PI3K/Akt and MAPK/JNK. The gene discussed is MAPK8; the disease is glioblastoma.